https://onlinelibrary.wiley.com/doi/abs/10.1002/mds.27878
https://www.ncbi.nlm.nih.gov/pubmed/31682033?dopt=Abstract
TITLE:
Systemic activation of Nrf2 pathway in Parkinson’s disease.
DESCRIPTION:
Systemic activation of Nrf2 pathway in Parkinson’s disease.
Mov Disord. 2019 Nov 04;:
Authors: Petrillo S, Schirinzi T, Di Lazzaro G, D’Amico J, Colona VL, Bertini E, Pierantozzi M, Mari L, Mercuri NB, Piemonte F, Pisani A
Abstract
BACKGROUND: Preclinical studies underlined the relevance of Nuclear factor erythroid 2-related factor 2 (Nrf2) transcription factor pathway in the pathogenesis of Parkinson’s disease (PD).
OBJECTIVE: The objective of this study was to explore Nrf2 pathway in vivo in PD, looking for novel disease biomarkers and therapeutic targets.
METHODS: The levels of Nrf2, the downstream effectors (NAD(P)H dehydrogenase [quinone] 1 (Nqo1) enzyme, glutathione metabolism enzymes Glutamate-cysteine ligase (GCL) and Glutathione Reductase (GR)), the upstream activators (redox state and mitochondrial dysfunction), and α-synuclein oligomers were assessed in the blood leukocytes of PD patients comparatively to controls. Biochemical data were correlated to clinical parameters.
RESULTS: In PD, Nrf2 was highly transcribed and expressed as well as its target effectors. The mitochondrial complex I activity was reduced and the oxidized form of glutathione prevailed, disclosing the presence of pathway’s activators. Also, α-synuclein oligomers levels were increased. Nrf2 transcript and oligomers levels correlated with PD duration.
CONCLUSIONS: Blood leukocytes mirror pathogenic mechanisms of PD, showing the systemic activation of the Nrf2 pathway and its link with synucleinopathy and clinical events. © 2019 International Parkinson and Movement Disorder Society.
PMID: 31682033 [PubMed – as supplied by publisher]
PMID:
PubMed:31682033
DATE FOUND:
11/05/19 06:05AM
LINK / URL:
https://www.ncbi.nlm.nih.gov/pubmed/31682033?dopt=Abstract